Direct-to-consumer communication on prescription only medicines via the internet in the Netherlands, a pilot study: Opinion of the pharmaceutical industry, patient associations and support groups

A. Mariette Fabius, Ka-Chun Cheung, Cristianne J. F. Rijcken, Christiaan H. Vinkers, Herre Talsma

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Objective: Investigation of the current application of direct-to-consumer (DTC) communication on prescription only medicines via the Internet in the Netherlands. Method: Questionnaires were sent by e-mail to 43 Dutch innovative pharmaceutical industries and 130 Patient Association and Support Groups (PASGs). Results: In this pilot study, the response of the pharmaceutical industry was rather low but the impression is that they were willing to invest in DTC communication. The majority of the websites of PASGs did not link to websites of pharmaceutical companies. The PASGs had no opinion whether patients can make a good distinction between DTC advertising and information on websites of the pharmaceutical industry nor about the quality. PASGs did not think unambiguously about the impact on the patient-doctor relationship. Conclusion: The impact of DTC communication on prescription only medicines via the internet is not yet clear in the Netherlands. © 2004 Kluwer Academic Publishers.
Original languageEnglish
Pages (from-to)169-172
JournalPharmacy World and Science
Volume26
Issue number3
DOIs
Publication statusPublished - 2004
Externally publishedYes

Cite this

@article{8e9fd8141009486c848f83a67d05c120,
title = "Direct-to-consumer communication on prescription only medicines via the internet in the Netherlands, a pilot study: Opinion of the pharmaceutical industry, patient associations and support groups",
abstract = "Objective: Investigation of the current application of direct-to-consumer (DTC) communication on prescription only medicines via the Internet in the Netherlands. Method: Questionnaires were sent by e-mail to 43 Dutch innovative pharmaceutical industries and 130 Patient Association and Support Groups (PASGs). Results: In this pilot study, the response of the pharmaceutical industry was rather low but the impression is that they were willing to invest in DTC communication. The majority of the websites of PASGs did not link to websites of pharmaceutical companies. The PASGs had no opinion whether patients can make a good distinction between DTC advertising and information on websites of the pharmaceutical industry nor about the quality. PASGs did not think unambiguously about the impact on the patient-doctor relationship. Conclusion: The impact of DTC communication on prescription only medicines via the internet is not yet clear in the Netherlands. {\circledC} 2004 Kluwer Academic Publishers.",
author = "Fabius, {A. Mariette} and Ka-Chun Cheung and Rijcken, {Cristianne J. F.} and Vinkers, {Christiaan H.} and Herre Talsma",
year = "2004",
doi = "10.1023/B:PHAR.0000026806.29066.e1",
language = "English",
volume = "26",
pages = "169--172",
journal = "Pharmacy World and Science",
issn = "0928-1231",
publisher = "Kluwer Academic Publishers",
number = "3",

}

Direct-to-consumer communication on prescription only medicines via the internet in the Netherlands, a pilot study: Opinion of the pharmaceutical industry, patient associations and support groups. / Fabius, A. Mariette; Cheung, Ka-Chun; Rijcken, Cristianne J. F.; Vinkers, Christiaan H.; Talsma, Herre.

In: Pharmacy World and Science, Vol. 26, No. 3, 2004, p. 169-172.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Direct-to-consumer communication on prescription only medicines via the internet in the Netherlands, a pilot study: Opinion of the pharmaceutical industry, patient associations and support groups

AU - Fabius, A. Mariette

AU - Cheung, Ka-Chun

AU - Rijcken, Cristianne J. F.

AU - Vinkers, Christiaan H.

AU - Talsma, Herre

PY - 2004

Y1 - 2004

N2 - Objective: Investigation of the current application of direct-to-consumer (DTC) communication on prescription only medicines via the Internet in the Netherlands. Method: Questionnaires were sent by e-mail to 43 Dutch innovative pharmaceutical industries and 130 Patient Association and Support Groups (PASGs). Results: In this pilot study, the response of the pharmaceutical industry was rather low but the impression is that they were willing to invest in DTC communication. The majority of the websites of PASGs did not link to websites of pharmaceutical companies. The PASGs had no opinion whether patients can make a good distinction between DTC advertising and information on websites of the pharmaceutical industry nor about the quality. PASGs did not think unambiguously about the impact on the patient-doctor relationship. Conclusion: The impact of DTC communication on prescription only medicines via the internet is not yet clear in the Netherlands. © 2004 Kluwer Academic Publishers.

AB - Objective: Investigation of the current application of direct-to-consumer (DTC) communication on prescription only medicines via the Internet in the Netherlands. Method: Questionnaires were sent by e-mail to 43 Dutch innovative pharmaceutical industries and 130 Patient Association and Support Groups (PASGs). Results: In this pilot study, the response of the pharmaceutical industry was rather low but the impression is that they were willing to invest in DTC communication. The majority of the websites of PASGs did not link to websites of pharmaceutical companies. The PASGs had no opinion whether patients can make a good distinction between DTC advertising and information on websites of the pharmaceutical industry nor about the quality. PASGs did not think unambiguously about the impact on the patient-doctor relationship. Conclusion: The impact of DTC communication on prescription only medicines via the internet is not yet clear in the Netherlands. © 2004 Kluwer Academic Publishers.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=3543044361&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/15230365

U2 - 10.1023/B:PHAR.0000026806.29066.e1

DO - 10.1023/B:PHAR.0000026806.29066.e1

M3 - Article

VL - 26

SP - 169

EP - 172

JO - Pharmacy World and Science

JF - Pharmacy World and Science

SN - 0928-1231

IS - 3

ER -